Human Genome drug falls short in midstage study
Human Genome Sciences Inc. said Wednesday a midstage study showed that a potential lung cancer treatment failed to work more effectively than chemotherapy alone in treating lung cancer.
The company said mapatumumab, in combination with the chemotherapy drugs paclitaxel and carboplatin, did not prompt a change in disease response or survival rates. The midstage study compared that combination with patients taking only chemotherapy. It focused on patients receiving initial treatment for lung cancer.
Human Genome Sciences did say that mapatumumab was well tolerated and it expects to present full results of the study later in 2010.
Shares edged up 4 cents to $31.75 in premarket trading.